Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds. 2020

Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, Cigli, Izmir, Turkey.

A series of thiazolopyrimidine derivatives was designed and synthesized as a Leishmania major pteridine reductase 1 (LmPTR1) enzyme inhibitor. Their LmPTR1 inhibitor activities were evaluated using the enzyme produced by Escherichia coli in a recombinant way. The antileishmanial activity of the selected compounds was tested in vitro against Leishmania sp. Additionally, the compounds were evaluated for cytotoxic activity against the murine macrophage cell line RAW 264.7. According to the results, four compounds displayed not only a potent in vitro antileishmanial activity against promastigote forms but also low cytotoxicity. Among them, compound L16 exhibited an antileishmanial activity for both the promastigote and amastigote forms of L. tropica, with IC50 values of 7.5 and 2.69 µM, respectively. In addition, molecular docking studies and molecular dynamics simulations were also carried out in this study. In light of these findings, the compounds provide a new potential scaffold for antileishmanial drug discovery.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000067996 RAW 264.7 Cells A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. RAW 264.7 Cell Line,264.7 Cell, RAW,264.7 Cells, RAW,Cell, RAW 264.7,Cells, RAW 264.7,RAW 264.7 Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
May 2018, European journal of medicinal chemistry,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
May 2014, ACS medicinal chemistry letters,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
January 2015, International journal of medicinal chemistry,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
December 2023, European journal of medicinal chemistry,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
September 2009, Bioorganic & medicinal chemistry letters,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
January 2005, Journal of medicinal chemistry,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
January 2015, European journal of medicinal chemistry,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
January 2010, Acta poloniae pharmaceutica,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
April 2018, Bioorganic & medicinal chemistry letters,
Huseyin Istanbullu, and Gulsah Bayraktar, and Hasan Akbaba, and Ibrahim Cavus, and Gunes Coban, and Bilge Debelec Butuner, and Ali Ahmet Kilimcioglu, and Ahmet Ozbilgin, and Vildan Alptuzun, and Ercin Erciyas
September 2019, Molecules (Basel, Switzerland),
Copied contents to your clipboard!